APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza (Flu) Antiviral Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026196 pages

Choose your research edition.

Industry ResearchInfluenza (Flu) Antiviral Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Influenza (Flu) Antiviral Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenza (Flu) Antiviral Drugs include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza (Flu) Antiviral Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza (Flu) Antiviral Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza (Flu) Antiviral Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza (Flu) Antiviral Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza (Flu) Antiviral Drugs Segment by Company

Allergan

Aurobindo Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers-Squibb

Cipla

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline (GSK)

Merck & Co. (MSD)

Novo Nordisk

Teva Pharmaceutical Industries

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Novartis

Johnson & Johnson

Sanofi

Teva

Takeda

Influenza (Flu) Antiviral Drugs Segment by Type

Neuraminidase Inhibitors

Reverse Transcriptase Inhibitors

Broad-spectrum Antiviral Drugs

Protein Inhibitors

Penetration and Dehulling Inhibitors

DNA Polymerase Inhibitors

Influenza (Flu) Antiviral Drugs Segment by Application

Clinic

Hospital

Household

Others

Influenza (Flu) Antiviral Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza (Flu) Antiviral Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Influenza (Flu) Antiviral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Influenza (Flu) Antiviral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Influenza (Flu) Antiviral Drugs Industry Trends Table 2. Influenza (Flu) Antiviral Drugs Industry Drivers Table 3. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges Table 4. Influenza (Flu) Antiviral Drugs Industry Restraints Table 5. Global Influenza (Flu) Antiviral Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Influenza (Flu) Antiviral Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Manufacturers Table 9. Global Influenza (Flu) Antiviral Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Influenza (Flu) Antiviral Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Influenza (Flu) Antiviral Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Influenza (Flu) Antiviral Drugs Manufacturers, Product Type & Application Table 13. Global Influenza (Flu) Antiviral Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza (Flu) Antiviral Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Neuraminidase Inhibitors Table 17. Major Manufacturers of Reverse Transcriptase Inhibitors Table 18. Major Manufacturers of Broad-spectrum Antiviral Drugs Table 19. Major Manufacturers of Protein Inhibitors Table 20. Major Manufacturers of Penetration and Dehulling Inhibitors Table 21. Major Manufacturers of DNA Polymerase Inhibitors Table 22. Global Influenza (Flu) Antiviral Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 24. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 25. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2026) Table 26. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2027-2032) Table 27. Global Influenza (Flu) Antiviral Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2026) & (K Units) Table 29. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2027-2032) & (K Units) Table 30. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Household Table 35. Major Manufacturers of Others Table 36. Global Influenza (Flu) Antiviral Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 38. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 39. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2026) Table 40. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2027-2032) Table 41. Global Influenza (Flu) Antiviral Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2026) & (K Units) Table 43. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2027-2032) & (K Units) Table 44. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2026) Table 45. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2027-2032) Table 46. Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units) Table 48. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Region (2021-2026) Table 49. Global Influenza (Flu) Antiviral Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 50. Global Influenza (Flu) Antiviral Drugs Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 53. North America Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 54. Europe Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 56. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 57. Asia Pacific Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 59. Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 60. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 62. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2027-2032) & (K Units) Table 63. Global Influenza (Flu) Antiviral Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2026) Table 67. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2027-2032) Table 68. Allergan Company Information Table 69. Allergan Business Overview Table 70. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio Table 72. Allergan Recent Development Table 73. Aurobindo Pharma Company Information Table 74. Aurobindo Pharma Business Overview Table 75. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio Table 77. Aurobindo Pharma Recent Development Table 78. Boehringer Ingelheim Company Information Table 79. Boehringer Ingelheim Business Overview Table 80. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio Table 82. Boehringer Ingelheim Recent Development Table 83. Bristol-Myers Squibb Company Information Table 84. Bristol-Myers Squibb Business Overview Table 85. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 87. Bristol-Myers Squibb Recent Development Table 88. Bristol-Myers-Squibb Company Information Table 89. Bristol-Myers-Squibb Business Overview Table 90. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 92. Bristol-Myers-Squibb Recent Development Table 93. Cipla Company Information Table 94. Cipla Business Overview Table 95. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio Table 97. Cipla Recent Development Table 98. F. Hoffmann-La Roche Company Information Table 99. F. Hoffmann-La Roche Business Overview Table 100. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 102. F. Hoffmann-La Roche Recent Development Table 103. Gilead Sciences Company Information Table 104. Gilead Sciences Business Overview Table 105. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio Table 107. Gilead Sciences Recent Development Table 108. GlaxoSmithKline (GSK) Company Information Table 109. GlaxoSmithKline (GSK) Business Overview Table 110. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio Table 112. GlaxoSmithKline (GSK) Recent Development Table 113. Merck & Co. (MSD) Company Information Table 114. Merck & Co. (MSD) Business Overview Table 115. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio Table 117. Merck & Co. (MSD) Recent Development Table 118. Novo Nordisk Company Information Table 119. Novo Nordisk Business Overview Table 120. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio Table 122. Novo Nordisk Recent Development Table 123. Teva Pharmaceutical Industries Company Information Table 124. Teva Pharmaceutical Industries Business Overview Table 125. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio Table 127. Teva Pharmaceutical Industries Recent Development Table 128. AstraZeneca Company Information Table 129. AstraZeneca Business Overview Table 130. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio Table 132. AstraZeneca Recent Development Table 133. AbbVie Company Information Table 134. AbbVie Business Overview Table 135. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio Table 137. AbbVie Recent Development Table 138. Amgen Company Information Table 139. Amgen Business Overview Table 140. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio Table 142. Amgen Recent Development Table 143. Bayer Company Information Table 144. Bayer Business Overview Table 145. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio Table 147. Bayer Recent Development Table 148. Pfizer Company Information Table 149. Pfizer Business Overview Table 150. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio Table 152. Pfizer Recent Development Table 153. Eli Lilly Company Information Table 154. Eli Lilly Business Overview Table 155. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio Table 157. Eli Lilly Recent Development Table 158. Roche Company Information Table 159. Roche Business Overview Table 160. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 162. Roche Recent Development Table 163. Mylan Company Information Table 164. Mylan Business Overview Table 165. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio Table 167. Mylan Recent Development Table 168. Novartis Company Information Table 169. Novartis Business Overview Table 170. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 171. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio Table 172. Novartis Recent Development Table 173. Johnson & Johnson Company Information Table 174. Johnson & Johnson Business Overview Table 175. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 176. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio Table 177. Johnson & Johnson Recent Development Table 178. Sanofi Company Information Table 179. Sanofi Business Overview Table 180. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 181. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio Table 182. Sanofi Recent Development Table 183. Teva Company Information Table 184. Teva Business Overview Table 185. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 186. Teva Influenza (Flu) Antiviral Drugs Product Portfolio Table 187. Teva Recent Development Table 188. Takeda Company Information Table 189. Takeda Business Overview Table 190. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 191. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio Table 192. Takeda Recent Development Table 193. Key Raw Materials Table 194. Raw Materials Key Suppliers Table 195. Influenza (Flu) Antiviral Drugs Distributors List Table 196. Influenza (Flu) Antiviral Drugs Customers List Table 197. Research Programs/Design for This Report Table 198. Authors List of This Report Table 199. Secondary Sources Table 200. Primary Sources List of Figures Figure 1. Influenza (Flu) Antiviral Drugs Product Image Figure 2. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units) Figure 5. Global Influenza (Flu) Antiviral Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Neuraminidase Inhibitors Image Figure 9. Reverse Transcriptase Inhibitors Image Figure 10. Broad-spectrum Antiviral Drugs Image Figure 11. Protein Inhibitors Image Figure 12. Penetration and Dehulling Inhibitors Image Figure 13. DNA Polymerase Inhibitors Image Figure 14. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Influenza (Flu) Antiviral Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032) Figure 17. Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Influenza (Flu) Antiviral Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Household Image Figure 23. Others Image Figure 24. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Influenza (Flu) Antiviral Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032) Figure 27. Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 28. Global Influenza (Flu) Antiviral Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032) Figure 30. North America Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. North America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 32. U.S. Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Canada Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Mexico Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 37. Germany Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. France Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. U.K. Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Italy Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Netherlands Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 44. China Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Japan Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South Korea Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Southeast Asia Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. India Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Australia Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2032) Figure 52. Brazil Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. South Africa Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Saudi Arabia Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Turkey Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Argentina Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. UAE Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Egypt Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Chile Influenza (Flu) Antiviral Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Global Influenza (Flu) Antiviral Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Figure 63. North America Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Europe Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Influenza (Flu) Antiviral Drugs Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Influenza (Flu) Antiviral Drugs Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Broad-spectrum Antiviral Drugs
  • Protein Inhibitors
  • Penetration and Dehulling Inhibitors
  • DNA Polymerase Inhibitors
Applications
  • Clinic
  • Hospital
  • Household
  • Others
Companies covered
  • Allergan
  • Aurobindo Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Merck & Co. (MSD)
  • Novo Nordisk
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenza (Flu) Antiviral Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenza (Flu) Antiviral Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Influenza (Flu) Antiviral Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Influenza (Flu) Antiviral Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Influenza (Flu) Antiviral Drugs Market Dynamics
  1. 2.1 Influenza (Flu) Antiviral Drugs Industry Trends
  2. 2.2 Influenza (Flu) Antiviral Drugs Industry Drivers
  3. 2.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza (Flu) Antiviral Drugs Industry Restraints
3 Influenza (Flu) Antiviral Drugs Market by Manufacturers
  1. 3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Influenza (Flu) Antiviral Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Influenza (Flu) Antiviral Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Influenza (Flu) Antiviral Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenza (Flu) Antiviral Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Influenza (Flu) Antiviral Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Influenza (Flu) Antiviral Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenza (Flu) Antiviral Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenza (Flu) Antiviral Drugs Tier 1, Tier 2, and Tier 3
4 Influenza (Flu) Antiviral Drugs Market by Type
  1. 4.1 Influenza (Flu) Antiviral Drugs Type Introduction
  2. 4.1.1 Neuraminidase Inhibitors
  3. 4.1.2 Reverse Transcriptase Inhibitors
  4. 4.1.3 Broad-spectrum Antiviral Drugs
  5. 4.1.4 Protein Inhibitors
  6. 4.1.5 Penetration and Dehulling Inhibitors
  7. 4.1.6 DNA Polymerase Inhibitors
  8. 4.2 Global Influenza (Flu) Antiviral Drugs Sales by Type
  9. 4.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2032)
  11. 4.2.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Influenza (Flu) Antiviral Drugs Revenue by Type
  13. 4.3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Type (2021-2032)
  15. 4.3.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2021-2032)
5 Influenza (Flu) Antiviral Drugs Market by Application
  1. 5.1 Influenza (Flu) Antiviral Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Household
  5. 5.1.4 Others
  6. 5.2 Global Influenza (Flu) Antiviral Drugs Sales by Application
  7. 5.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Influenza (Flu) Antiviral Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Influenza (Flu) Antiviral Drugs Revenue by Application
  11. 5.3.1 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Influenza (Flu) Antiviral Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2021-2032)
6 Global Influenza (Flu) Antiviral Drugs Sales by Region
  1. 6.1 Global Influenza (Flu) Antiviral Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Influenza (Flu) Antiviral Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Influenza (Flu) Antiviral Drugs Revenue by Region
  1. 7.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region
  2. 7.1.1 Global Influenza (Flu) Antiviral Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Influenza (Flu) Antiviral Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Influenza (Flu) Antiviral Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Influenza (Flu) Antiviral Drugs Revenue (2021-2032)
  8. 7.2.2 North America Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Influenza (Flu) Antiviral Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Influenza (Flu) Antiviral Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Allergan
  2. 8.1.1 Allergan Company Information
  3. 8.1.2 Allergan Business Overview
  4. 8.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
  6. 8.1.5 Allergan Recent Developments
  7. 8.2 Aurobindo Pharma
  8. 8.2.1 Aurobindo Pharma Company Information
  9. 8.2.2 Aurobindo Pharma Business Overview
  10. 8.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
  12. 8.2.5 Aurobindo Pharma Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Bristol-Myers-Squibb
  26. 8.5.1 Bristol-Myers-Squibb Company Information
  27. 8.5.2 Bristol-Myers-Squibb Business Overview
  28. 8.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  30. 8.5.5 Bristol-Myers-Squibb Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 F. Hoffmann-La Roche
  38. 8.7.1 F. Hoffmann-La Roche Company Information
  39. 8.7.2 F. Hoffmann-La Roche Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Recent Developments
  43. 8.8 Gilead Sciences
  44. 8.8.1 Gilead Sciences Company Information
  45. 8.8.2 Gilead Sciences Business Overview
  46. 8.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
  48. 8.8.5 Gilead Sciences Recent Developments
  49. 8.9 GlaxoSmithKline (GSK)
  50. 8.9.1 GlaxoSmithKline (GSK) Company Information
  51. 8.9.2 GlaxoSmithKline (GSK) Business Overview
  52. 8.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
  54. 8.9.5 GlaxoSmithKline (GSK) Recent Developments
  55. 8.10 Merck & Co. (MSD)
  56. 8.10.1 Merck & Co. (MSD) Company Information
  57. 8.10.2 Merck & Co. (MSD) Business Overview
  58. 8.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
  60. 8.10.5 Merck & Co. (MSD) Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Teva Pharmaceutical Industries
  68. 8.12.1 Teva Pharmaceutical Industries Company Information
  69. 8.12.2 Teva Pharmaceutical Industries Business Overview
  70. 8.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
  72. 8.12.5 Teva Pharmaceutical Industries Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 AbbVie
  80. 8.14.1 AbbVie Company Information
  81. 8.14.2 AbbVie Business Overview
  82. 8.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
  84. 8.14.5 AbbVie Recent Developments
  85. 8.15 Amgen
  86. 8.15.1 Amgen Company Information
  87. 8.15.2 Amgen Business Overview
  88. 8.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
  90. 8.15.5 Amgen Recent Developments
  91. 8.16 Bayer
  92. 8.16.1 Bayer Company Information
  93. 8.16.2 Bayer Business Overview
  94. 8.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
  96. 8.16.5 Bayer Recent Developments
  97. 8.17 Pfizer
  98. 8.17.1 Pfizer Company Information
  99. 8.17.2 Pfizer Business Overview
  100. 8.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
  102. 8.17.5 Pfizer Recent Developments
  103. 8.18 Eli Lilly
  104. 8.18.1 Eli Lilly Company Information
  105. 8.18.2 Eli Lilly Business Overview
  106. 8.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
  108. 8.18.5 Eli Lilly Recent Developments
  109. 8.19 Roche
  110. 8.19.1 Roche Company Information
  111. 8.19.2 Roche Business Overview
  112. 8.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  114. 8.19.5 Roche Recent Developments
  115. 8.20 Mylan
  116. 8.20.1 Mylan Company Information
  117. 8.20.2 Mylan Business Overview
  118. 8.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
  120. 8.20.5 Mylan Recent Developments
  121. 8.21 Novartis
  122. 8.21.1 Novartis Company Information
  123. 8.21.2 Novartis Business Overview
  124. 8.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
  126. 8.21.5 Novartis Recent Developments
  127. 8.22 Johnson & Johnson
  128. 8.22.1 Johnson & Johnson Company Information
  129. 8.22.2 Johnson & Johnson Business Overview
  130. 8.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
  132. 8.22.5 Johnson & Johnson Recent Developments
  133. 8.23 Sanofi
  134. 8.23.1 Sanofi Company Information
  135. 8.23.2 Sanofi Business Overview
  136. 8.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
  138. 8.23.5 Sanofi Recent Developments
  139. 8.24 Teva
  140. 8.24.1 Teva Company Information
  141. 8.24.2 Teva Business Overview
  142. 8.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
  144. 8.24.5 Teva Recent Developments
  145. 8.25 Takeda
  146. 8.25.1 Takeda Company Information
  147. 8.25.2 Takeda Business Overview
  148. 8.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
  150. 8.25.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
  2. 9.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza (Flu) Antiviral Drugs Production Mode & Process
  6. 9.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza (Flu) Antiviral Drugs Distributors
  9. 9.2.3 Influenza (Flu) Antiviral Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst